CRDF
Cardiff Oncology·NASDAQ
--
--(--)
--
--(--)
6.63 / 10
Outperform
Sentiment is upbeat (6.63/10, Outperform) with a strong fund‑flow score of 7.72 (good). Large and extra‑large investors show net inflows, while small and medium investors are net outflows. One analyst rates the stock a Buy with 100% historical success, reinforcing a bullish tilt.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-25
InstitutionPiper Sandler
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for CRDF?
- CRDF holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.63/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
